Literature DB >> 2871757

Pulmonary edema. Complication in the management of sickle cell pain crisis.

J Haynes, R C Allison.   

Abstract

Over a 12-month period, there were 51 admissions for sickle cell pain crisis. Of these, the course of four patients (two with hemoglobin SS, one with hemoglobin SC, and one with hemoglobin S-Thal) was complicated by the development of pulmonary edema. Pulmonary edema complicating the management of sickle cell pain crisis has not previously been described. Vigorous fluid replacement with hypotonic saline and parenteral narcotic analgesics are conventional modalities of therapy, but may contribute to the development of pulmonary edema. Narcotic analgesics causing increased permeability are well established. In pulmonary vascular beds predisposed to injury, hypotonic saline administration causing an increased hydrostatic pressure and decreased oncotic pressure may further compound pulmonary edema development. On the basis of the experience in this study, a conservative approach to the use of fluid administration and narcotic analgesics is advised.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2871757     DOI: 10.1016/0002-9343(86)90624-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  13 in total

1.  Practical management of pain in sickling disorders.

Authors:  R Grundy; R Howard; J Evans
Journal:  Arch Dis Child       Date:  1993-08       Impact factor: 3.791

2.  Hemin Causes Lung Microvascular Endothelial Barrier Dysfunction by Necroptotic Cell Death.

Authors:  Sunit Singla; Justin R Sysol; Benjamin Dille; Nicole Jones; Jiwang Chen; Roberto F Machado
Journal:  Am J Respir Cell Mol Biol       Date:  2017-09       Impact factor: 6.914

3.  Early intermittent noninvasive ventilation for acute chest syndrome in adults with sickle cell disease: a pilot study.

Authors:  Muriel Fartoukh; Yannick Lefort; Anoosha Habibi; Dora Bachir; Frédéric Galacteros; Bertrand Godeau; Bernard Maitre; Laurent Brochard
Journal:  Intensive Care Med       Date:  2010-05-18       Impact factor: 17.440

Review 4.  Sickle Cell Disease and Stroke: Diagnosis and Management.

Authors:  Courtney Lawrence; Jennifer Webb
Journal:  Curr Neurol Neurosci Rep       Date:  2016-03       Impact factor: 5.081

5.  Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE).

Authors:  Lori Styles; Carrie G Wager; Richard J Labotka; Kim Smith-Whitley; Alexis A Thompson; Peter A Lane; Lillian E C McMahon; Robin Miller; Susan D Roseff; Rathi V Iyer; Lewis L Hsu; Oswaldo L Castro; Kenneth I Ataga; Onyinye Onyekwere; Maureen Okam; Rita Bellevue; Scott T Miller
Journal:  Br J Haematol       Date:  2012-03-30       Impact factor: 6.998

6.  Inpatient management of sickle cell pain: a 'snapshot' of current practice.

Authors:  Scott T Miller; Hae-Young Kim; Debra Weiner; Carrie G Wager; Dianne Gallagher; Lori Styles; Carlton D Dampier
Journal:  Am J Hematol       Date:  2012-01-09       Impact factor: 10.047

Review 7.  Pulmonary manifestations of sickle cell disease.

Authors:  A K Siddiqui; S Ahmed
Journal:  Postgrad Med J       Date:  2003-07       Impact factor: 2.401

8.  Acute chest syndrome after laparoscopic splenectomy in children with sickle cell disease: operative time dependent?

Authors:  A Bonnard; M Masmoudi; B Boimond; C Capito; L Holvoet; A Skhiri; A El Ghoneimi
Journal:  Pediatr Surg Int       Date:  2014-09-23       Impact factor: 1.827

9.  Impact of fluid overload and infection on respiratory adverse event development during induction therapy for childhood acute myeloid leukemia.

Authors:  Lane H Miller; Frank Keller; Ann Mertens; Mitchel Klein; Kristen Allen; Sharon Castellino; William G Woods
Journal:  Pediatr Blood Cancer       Date:  2019-09-10       Impact factor: 3.167

Review 10.  Acute Chest Syndrome in Children with Sickle Cell Disease.

Authors:  Shilpa Jain; Nitya Bakshi; Lakshmanan Krishnamurti
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2017-12-01       Impact factor: 1.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.